Last week, the first ‘living drug’ in India received approval, marking a significant milestone in the country’s cancer care landscape. https://theprint.in/health/all-about-indias-1st-living-drug-that-uses-patients-own-genetically-engineered-cells-to-fight-cancer/1805864/
The Central Drugs Standard Control Organisation (CDSCO), on 13 October, approved the first CAR (Chimeric Antigen Receptor) T-cell therapy — a cutting-edge immunotherapy developed by ImmunoACT, a company incubated at the Indian Institute of Technology Bombay, for the treatment of leukemia and refractory or relapsed lymphoma (cancers of the lymph system).